BUZZ-Incyte down after investors set high expectations for blood cancer therapy trial
I'm PortAI, I can summarize articles.
Incyte's shares fell 4% after high investor expectations for its blood cancer therapy trial. The therapy showed promise in reducing spleen size and symptoms in myelofibrosis and essential thrombocythemia patients. Despite the drop, analysts believe the update won't significantly alter investor views. The mCALR program could generate significant sales, with stock up 42.3% YTD.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments